Logo image of ALT

ALTIMMUNE INC (ALT) Stock Price, Quote, News and Overview

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

6.43  -0.2 (-3.02%)

After market: 6.43 0 (0%)

ALT Quote, Performance and Key Statistics

ALTIMMUNE INC

NASDAQ:ALT (2/21/2025, 8:00:56 PM)

After market: 6.43 0 (0%)

6.43

-0.2 (-3.02%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.84
52 Week Low5.28
Market Cap457.30M
Shares71.12M
Float70.42M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-25 2025-03-25/amc
IPO10-06 2005-10-06


ALT short term performance overview.The bars show the price performance of ALT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20 -25

ALT long term performance overview.The bars show the price performance of ALT in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ALT is 6.43 USD. In the past month the price decreased by -8.92%. In the past year, price decreased by -30.11%.

ALTIMMUNE INC / ALT Daily stock chart

ALT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ALT

Company Profile

ALT logo image Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 59 full-time employees. The company went IPO on 2005-10-06. The firm's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The firm has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The company is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The firm has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Company Info

ALTIMMUNE INC

910 Clopper Road, Suite 201S

Gaithersburg MARYLAND 20878 US

CEO: Vipin K. Garg

Employees: 59

Company Website: https://altimmune.com/

Investor Relations: https://ir.altimmune.com/

Phone: 12406541450

ALTIMMUNE INC / ALT FAQ

What is the stock price of ALTIMMUNE INC today?

The current stock price of ALT is 6.43 USD. The price decreased by -3.02% in the last trading session.


What is the ticker symbol for ALTIMMUNE INC stock?

The exchange symbol of ALTIMMUNE INC is ALT and it is listed on the Nasdaq exchange.


On which exchange is ALT stock listed?

ALT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALTIMMUNE INC stock?

12 analysts have analysed ALT and the average price target is 22.15 USD. This implies a price increase of 244.46% is expected in the next year compared to the current price of 6.43. Check the ALTIMMUNE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALTIMMUNE INC worth?

ALTIMMUNE INC (ALT) has a market capitalization of 457.30M USD. This makes ALT a Small Cap stock.


How many employees does ALTIMMUNE INC have?

ALTIMMUNE INC (ALT) currently has 59 employees.


What are the support and resistance levels for ALTIMMUNE INC (ALT) stock?

ALTIMMUNE INC (ALT) has a support level at 6.25 and a resistance level at 6.99. Check the full technical report for a detailed analysis of ALT support and resistance levels.


Is ALTIMMUNE INC (ALT) expected to grow?

The Revenue of ALTIMMUNE INC (ALT) is expected to decline by -98.05% in the next year. Check the estimates tab for more information on the ALT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALTIMMUNE INC (ALT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALTIMMUNE INC (ALT) stock pay dividends?

ALT does not pay a dividend.


When does ALTIMMUNE INC (ALT) report earnings?

ALTIMMUNE INC (ALT) will report earnings on 2025-03-25, after the market close.


What is the Price/Earnings (PE) ratio of ALTIMMUNE INC (ALT)?

ALTIMMUNE INC (ALT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).


What is the Short Interest ratio of ALTIMMUNE INC (ALT) stock?

The outstanding short interest for ALTIMMUNE INC (ALT) is 33.11% of its float. Check the ownership tab for more information on the ALT short interest.


ALT Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALT. No worries on liquidiy or solvency for ALT as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALT Financial Highlights

Over the last trailing twelve months ALT reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS increased by 12.99% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -70.01%
ROE -77.61%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%17.95%
Sales Q2Q%-98.62%
EPS 1Y (TTM)12.99%
Revenue 1Y (TTM)-81.43%

ALT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ALT. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 5.76% and a revenue growth -98.05% for ALT


Ownership
Inst Owners60.57%
Ins Owners0.75%
Short Float %33.11%
Short Ratio8.79
Analysts
Analysts81.67
Price Target22.15 (244.48%)
EPS Next Y5.76%
Revenue Next Year-98.05%